Healthcare professional engagement
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
T40: when a number is not just a number
Proud to be ranked 3rd among the Top 10 UK-focused agencies, along with other categories, Grace Communications finds inspiration in being included in PMLive’s Top 40 Creative Healthcare Agencies 2025.
Cuttsy+Cuttsy becomes employee owned
Cuttsy+Cuttsy announces its transition to employee ownership, celebrating 15 years of prioritising clients, patients, and its team while continuing under the leadership of founders Caroline Benson and Mathew Cutts.
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
Sanofi’s amlitelimab shows positive results in atopic dermatitis
Newly released study data shows consistent reductions in disease severity
Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms
Some patients found the treatment reduced itch and sleep disturbance within just two days
InflaRx reports positive phase 2 results for HS and CSU treatments
Topline results demonstrated treatment efficacy for both conditions
J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis
The drug is the first IL-23 inhibitor approved for children from the age of six